Comparison of proportional and differential odds models for mixed-effects analysis of categorical data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 5, 2008, Pages 483-501

  Kjellsson, Maria C ^a   Zingmark, Per Henrik ^b   Jonsson, E Niclas ^a,c   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c Exprimo NV   (Belgium)

Author keywords

Categorical data; Differential odds model; Mixed effects models; NONMEM; Pharmacodynamics; Proportional odds model

Indexed keywords

CLOMETHIAZOLE; FOSPROPOFOL; IRINOTECAN; KETOROLAC; LOTRAFIBAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ATM 027; OXYBUTYNIN; PLACEBO; PROPOFOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 11577; T LYMPHOCYTE RECEPTOR; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ALLERGIC RHINITIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BOOTSTRAPPING; BREAST CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIFFERENTIAL ODDS MODEL; HISTOGRAM; MATHEMATICAL MODEL; MIXED EFFECTS MODEL; MULTIPLE SCLEROSIS; NEUTROPHIL COUNT; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROPORTIONAL ODDS MODEL; RECEPTOR DENSITY; SEDATION; SMOKING CESSATION; STROKE;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; PHARMACOLOGY; PROBABILITY; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TREATMENT OUTCOME;

EID: 57749084500     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9098-0     Document Type: Article

References (25)

1. Agresti A (2002) Categorical data analysis. Wiley, Hoboken, NJ
2. LB Sheiner 1994 A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data Clin Pharmacol Ther 56 309 322
3. PH Zingmark C Edenius MO Karlsson 2004 Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T-cells by monoclonal antibody ATM-027 in patients with multiple sclerosis as measured by FACS Br J Clin Pharmacol 58 378 389 10.1111/j.1365-2125.2004.02177.x
4. JW Mandema DR Stanski 1996 Population pharmacodynamic model for ketorolac analgesia Clin Pharmacol Ther 60 619 635 10.1016/S0009-9236(96)90210-6
5. SK Gupta G Sathyan EA Lindemulder PL Ho LB Sheiner L Aarons 1999 Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationship Clin Pharmacol Ther 65 672 685 10.1016/S0009-9236(99)90089-9
6. R Gomeni L Teneggi L Iavarone L Squassante A Bye 2001 Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling Pharm Res 18 537 543 10.1023/A:1011070814530
7. DJ Lunn J Wakefield A Racine-Poon 2001 Cumulative logit models for ordinal data: a case involving allergic rhinitis severity scores Stat Med 20 2261 2285 10.1002/sim.922
8. DR Mould M Chapelsky J Aluri J Swagdis R Samuels J Granett 2001 A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients Clin Pharmacol Ther 69 210 222 10.1067/mcp.2001.114925
9. DR Mould NHG Holford JHM Schellens JH Beijner PR Hutson H Rosing 2002 Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors Clin Pharmacol Ther 71 334 348 10.1067/mcp.2002.123553
10. SR Johnston T Hickish P Ellis S Houston L Kelland M Dowsett 2003 Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R11577, in advanced breast cancer J Clin Oncol 21 2492 2499 10.1200/JCO.2003.10.064
11. KG Kowalski L McFadyen MM Hutmacher B Frame R Miller 2003 A two-part mixture model for longitudinal adverse event severity data J Pharmacokinet Pharmacodyn 30 315 336 10.1023/B:JOPA.0000008157.26321.3c
12. M Cullberg UG Eriksson K Wåhlander H Eriksson S Shulman MO Karlsson 2005 Pharmacokinetics of ximelagatran and relationships to clinical response in acute deep vein thrombosis Clin Pharmacol Ther 77 279 290 10.1016/j.clpt.2004. 11.001
13. R Xie RHJ Mathijssen A Sparreboom J Verweij MO Karlsson 2002 Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea Clin Pharmacol Ther 72 265 275 10.1067/mcp.2002.126741
14. PH Zingmark M Ekblom T Odergren T Ashwood P Lyden MO Karlsson 2003 Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients Br J Clin Pharmacol 56 173 183 10.1046/j.0306-5251.2003.01850.x
15. CAJ Knibbe KP Zuideveld J DeJongh PFM Kuks LPHJ Aarts M Danhof 2002 Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patents: a comparison between propofol 6% and propofol 1 Clin Pharmacol Ther 72 670 684 10.1067/mcp.2002.129500
16. E Olofsen R Romberg H Bijl R Mooren F Engbers B Kest 2005 Alfentanil and placebo analgesia No sex difference detected in models of experimental pain. Anesthesiology 103 130 139 10.1097/00000542-200507000-00020
17. Gibiansky E, Gibiansky L (2007) Population PK/PD model of GPI 15715 and GPI 15715-derived propofol in sedation and comparison of PK/PD models for ordered categorical observations. In: Abstracts of the annual meeting of the population approach group in Europe. http://www.page-meeting.org/?abstract=735. Accessed 10/03/07
18. BG Armstrong M Sloan 1989 Ordinal regression models for epidemiologic data Am J Epidemiol 129 191 204
19. PO Gisleskog MO Karlsson SL Beal 2002 Use of prior information to stabilize a population data analysis J Pharmacokinet Pharmacodyn 29 473 505 10.1023/A:1022972420004
20. Beal SL, Sheiner LB (eds) (1989-1998) Users guides, NONMEM Icon Development Solutions, Elliot City, MD
21. DO Stram JW Lee 1994 Variance components testing in the longitudinal mixed effects model Biometrics 50 1171 1177 10.2307/2533455
22. Pinheiro JC, Bates DM (2000) Mixed-effects models in S and S-plus. In: (eds) Statistics and computing. Springer, New York
23. U Wählby MR Bouw EN Jonsson MO Karlsson 2002 Assessment of type I error rates for the statistical sub-model in NONMEM J Pharmacokinet Pharmacodyn 29 251 269 10.1023/A:1020254823597
24. B Efron 1979 Bootstrap method: another look at the Jackknife Ann Stat 7 1 26 10.1214/aos/1176344552
25. SC Scott MS Goldberg NE Mayo 1997 Statistical assessment of ordinal outcomes in comparative studies J Clin Epidemiol 50 45 55 10.1016/S0895-4356(96) 00312-5